Can you provide an overview of the actionable targets--such as EGFR, ALK, and MET--that are relevant for patients with NSCLC, and how to deploy NGS technologies to identify molecular drivers?

Can you provide an overview of the actionable targets--such as EGFR, ALK, and MET--that are relevant for patients with NSCLC, and how to deploy NGS technologies to identify molecular drivers?

Can you provide an overview of the clinically actionable targets—such as EGFR, ALK, and MET—that are relevant for patients with NSCLC, and how to optimally deploy NGS technologies to identify molecular drivers in the clinic setting?


Created by

CMEducation Resources IQ&A Interactive Intelligence Zone

Presenter

Alexander Drilon, MD

Alexander Drilon, MD

Medical Oncologist
Memorial Sloan Kettering Cancer Center
New York, NY, USA